Intraarterial Administration Boosts 177 Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients

The Journal of Nuclear Medicine

article

Evert-Jan P.A. Vonken¹  Rutger C.G. Bruijnen¹  Tom J. Snijders²  Tatjana Seute²  Marnix G.E.H. Lam¹  Bart de Keizer¹  Arthur J.A.T. Braat¹ 

[1] Department of Radiology and Nuclear Medicine, University Medical Center Utrecht;Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht

关键词: meningioma;    PRRT;    intraarterial;    somatostatin receptor;   

DOI  :  10.2967/jnumed.121.262491

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Intravenous 177Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. Methods: Patients underwent at least 1 intravenous 177Lu-HA-DOTATATE treatment first and subsequent intraarterial cycles. Inpatient and intrapatient comparison was based on posttreatment 177Lu-HA-DOTATATE imaging 24 h after injection. The technical success rate and adverse events were recorded. Results: Four patients provided informed consent. The technical success rate was 100%, and no angiography-related or unexpected adverse events occurred. Intrapatient comparison showed an increased target lesion accumulation on both planar imaging (mean, +220%) and SPECT/CT (mean, +398%) after intraarterial administration, compared with intravenous administration. No unexpected adverse events occurred during follow-up. Conclusion: Intraarterial peptide receptor radionuclide therapy significantly increases tracer accumulation and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intraarterial peptide receptor radionuclide therapy are needed to determine the gain in efficacy and survival.

【 授权许可】

CC BY